RegulatoryCompany release

Filana targets Phase 2a simufilam epilepsy trial screening by Q1 2027 after FDA lifts hold

🇺🇸 Filana Therapeutics, Inc. (FLNA) · Thu 05 Nov 2026

The US firm says the FDA cleared its IND for simufilam in tuberous sclerosis complex-related epilepsy in September, as it reported Q3 results and a securities settlement escrow payment.

Filana Therapeutics has said the US Food and Drug Administration lifted the clinical hold on its investigational new drug application for simufilam in epilepsy linked to tuberous sclerosis complex. The company disclosed the September decision alongside its third-quarter 2026 results, published on 5 November 2026.

The company is preparing a randomised, double-blind Phase 2a study in about 40 patients at roughly 13 US sites. It expects screening to begin by the first quarter of 2027. The summary provided does not give details of the dosing, endpoints or the reason for the original hold.

On the financial side, Filana reported $47.0 million in cash and a net loss of $10.7 million for the quarter. It also reported a $31.25 million escrow payment tied to a potential settlement of securities litigation. No further terms of that settlement were provided in the material reviewed.

As general context, a clinical hold is an FDA order that stops a trial from starting or continuing, and it is lifted only once the agency is satisfied that the issues behind it have been addressed.

What it means for your team

  • Sponsors and CROs with TSC programmes should note a new US Phase 2a opportunity, with about 13 sites planned and screening targeted for Q1 2027.
  • Clinical operations and safety teams should watch for the trial's registration details, as the available information does not describe the protocol design or the grounds for the earlier hold.
  • Market-access and business-development observers should treat the cash position and the securities litigation escrow as relevant to the company's ability to fund the study, without drawing conclusions beyond the reported figures.

Company's press release (SEC filing): Filana Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Filana Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →